Inari Medical, Inc. (NASDAQ: NARI) reported Q2 EPS of $0.08, in-line with the analyst estimate of $0.08. Revenue for the quarter came in at $63.5 million versus the consensus estimate of $59.65 million.

“Our second quarter was highly successful, especially in ways most important to our mission to treat and transform the lives of our patients,” said Bill Hoffman, CEO of Inari Medical. “We treated a record number of patients, reported best in class data from our CLOUT registry, and announced FDA clearance of FlowSaver, making bloodless thrombectomy a reality across the entire Inari portfolio. We continue to invest aggressively to expand our capabilities to treat even more patients and address more unmet needs. We love every second of this work, and we are so thankful to all of you for believing and committing along with us in this mission.”

GUIDANCE:

Inari Medical, Inc. sees FY2021 revenue of $250-255 million, versus the consensus of $246.95 million.

For earnings history and earnings-related data on Inari Medical, Inc. (NARI) click here.